CA2336904A1 - Novel fluorescent lanthanide chelates - Google Patents

Novel fluorescent lanthanide chelates Download PDF

Info

Publication number
CA2336904A1
CA2336904A1 CA002336904A CA2336904A CA2336904A1 CA 2336904 A1 CA2336904 A1 CA 2336904A1 CA 002336904 A CA002336904 A CA 002336904A CA 2336904 A CA2336904 A CA 2336904A CA 2336904 A1 CA2336904 A1 CA 2336904A1
Authority
CA
Canada
Prior art keywords
group
dtpa
iii
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002336904A
Other languages
French (fr)
Inventor
George Wai-Kin Chan
Robert P. Hertzberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2336904A1 publication Critical patent/CA2336904A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0026Acridine dyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052Small organic molecules
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16Isothiocyanates
    • C07C331/28Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings

Abstract

The present invention provides complexing agents of Formula (I) which contain novel photosensitizers and produce long-lived fluorescence for use in bioaffinity assays, especially HTRF (homogeneous time-resolved fluorescence) assays.

Description

NOVEL FLUORESCENT LANTHANIDE CHELATES
FIELD OF INVENTION
The present invention relates to the identification and preparation of organic agents that can complex lanthanide cations. In particular, this invention relates to complexing agents which contain novel photosensitizers and can produce long-lived fluorescence for use in bioaffinity assays, especially HTRF (homogeneous time-resolved fluorescence) assays.
BACKGROUND OF THE INVENTION
A wide variety of bioassays are used in the pharmaceutical industry to identify drug development candidate compounds. Recent advances in the identification of pharmaceutical targets, together with the vastly increased output of new compounds using techniques such as combinatorial chemistry have created a need to increase bioassay throughput (number of samples measured per unit time) drastically to meet discovery objectives. Robotics, miniaturization and homogeneous assay formats have all been incorporated into high throughput screening (HTS) assays to increase throughput. Ideally, an analytical technique suitable for both miniaturization and homogeneous assay formats must provide maximal detection sensitivity and interaction in situ, while requiring only minimal assay time and liquid handling (e.g., separation and filtration).
Present analytical techniques, such as those which use radiolabels, are unsatisfactory for HTS
use because they lack sensitivity, require large sample size and manual liquid handling.
Compared to traditional radiolabels, fluorescent labels have more desirable lifetime, solubility and sensitivity properties for use in HTS assays. The unique lifetime properties of fluorescent labels also meet the needs of fluorescence polarization (FP) and fluorescence correlation spectroscopy (FCS) in the investigation of slow rotational and translational changes in macromolecules.
Traditional fluorescent labels such as organic dyes, e.g., fluoresceins and rhodamines, have long been employed as bioanalytical tools in immunoassays.
More recently; lanthanide chelates have been developed as fluorescence agents for use in the bioassay field. These lanthanide chelates _have been reviewed. See Dickson, J.
Photochemistrv and Photobiolo~v, 27 (1995) 3-19; and Mathis, J. Clinical Lig~d Assav 20 (I997)141-145.

The lanthanide chelates are capable of producing long-lived and long wavelength fluorescent emissions upon excitation. In time-delay measurements, they have demonstrated clear advantages over conventional fluorescent labels, in particular less quenching and background interference, while exhibiting increased detection sensitivity. In addition to these advantages, many lanthanide chelates have demonstrated superior solubility properties and are able to efficiently transfer energy from their excited states to neighboring acceptor molecules. These advantages render lanthanide chelates ideal agents for HTRF use, especially for developing high-throughput automated and miniaturized binding assays, inncluding immunoassays, DNA hybridization assays, receptor binding assays, enzyme assays, cell-based assays, immunocytochemcial or immunohistochemical assays.
A number of lanthanide (e.g. terbium, europium) complexes are known, but only three classes of lanthanide chelates, exemplified by the compounds shown in Table I below, are considered to be useful in HTRF:
Table I
Cryptates (Packard) bipyridine type; i.e.
DTPA Chelates (Berkeley) ""e diethylenetriamine-pentaacetic 0 N N NH(CH2~OH
-~ ~ ~ ~ ~---.
acid type; i.e. " H
O HOOC COON COON O
Eu+3.
PMDA Chelates (Wallac) "~" N °°°F' pyridylmethylamine-diacetic ~ ~ / ~N ~°°eH Eu+3 HzN -acid type; i.e. /~°°°"
N
---COON
3 PC'T/US99/15366 These chelates have been described as having chemical stability, long-lived fluorescence (greater than 0.1 ms lifetime) after bioconjugation and significant energy-transfer in specific bioaffinity assays. US5162508, issued to Lehn, et al. on November 10, 1992 discloses bipyridine cryptates. Polycarboxylate chelators with TEKES type photosensitizers (EP 0203047 AI) and terpyridine type photosensitizers (EP
0649020 A1) are known. International Publication No. WO 96/00901 of Selvin et al., having an International Publication Date of January 11, 1996, discloses diethylenetriaminepentaacetic acid (DTPA) chelates which used carbostyril as sensitizes. Bailey, et al., Analyst, 109, (1984) 1449; Ando, et al. Biochim. Bioph~s. Acta, 1102, (1992) 186; and Heyduk et al., Anal. Biochemistry, 248, (1997) 216 also describe DTPA lanthanide chelates which contain different sensitizers. Additional DTPA chelates with other sensitizers and other tracer metals are known for diagnostic or imaging use (e.g., EP 0450742 A1).
The lanthanide chelates provided by the present invention include novel sensitizers which differ from carbostyril and other known chelates. More specifically, these novel sensitizers impart onto the present chelates advantageous physicochemical properties pertaining to excitation wavelength, lifetime, quantum yield, quenching effect, complex stability, photostability, solubility, charge, nonspecific protein interaction, biocoupling efficiency and ease of preparation. Such advantages are desirable to provide a diversity of novel fluorescent probes for use in, and development of, HTRF assays.
SUMMARY OF THE INVENTION
An object of the present invention is to provide novel lanthanide chelate compounds, and a method for using such compounds in fluorescence detection-based techniques or bioassays.
Accordingly, in the first aspect, this invention provides a compound according to Formula I.
In still another aspect, this invention provides a method for using the compounds of Formula I in fluorescence detection-based techniques or bioassays.
In yet another aspect, this invention provides a kit for fluorescence detection-based techniques or bioassays which use the compounds of Formula I as the basis for signal detection and measurement.

DETAILED DESCRIPTION OF THE INVENTION
Each compound of the present invention comprises four functional parts: a lanthanide metal cation (e.g. Tb III, Eu III, Sm III, Dy III), a chelator for the lanthanide metal, a photosensitizer for photoexcitation and energy transfer, and a linker for bioconjugation to the target biomolecule, that is, the biomolecule being measured using a fluorescence detection -based spectroscopic technique or bioassay.
The present invention provides compounds of Formula I:
O O
R2 ~ ~R1 N~N~N
n O
O OH O OH
OH
wherein:
[~N/~]n is a chelator selected from the group consisting of:
diethylenetriaminepentaacetic acid (DTPA) (n = I) or triethylenetetraaminehexaacetic acid (TTHA) (n =2) or a polyaminocarboxylate derivative of DTPA or TTHA, preferably DTPA, which chelates a lanthanide metal cation, preferably selected from the group consisting of: Tb III, Eu III, Sm III, and Dy III.
The sensitizer R1 is usually related to an aromatic or heteroaromatic amine whose chromophore plays a vital role in excitation and energy transfer. Superior sensitizers usually have highly conjugated systems and an added capacity for lanthanide complexation.
We have found several sensitizers, belonging to two structural classes-phenones and quinolines - that provide highly fluorescent compounds of Formula I. R1 is more preferably selected from the following group: aminoacetophenones (AAP), aminobenzophenones (ABP), aminofluorenones (AF), aminoxantones (AX), amino-azaxanthones (AAX), aminoanthraquinones (AAQ), and aminoacridones (AAC):
WO 00/01663 PC'T/US99/15366 NHz / \ I / NHz i O AAP O
ABP

NH2 _ , , NHz \ / \ /
O AX

NHz NHz \ /
O AAX AAQ

NHz O AAC
wherein for each nucleus, the amino group NH2 may be attached at one of any possible positions on the phenyl ring. The point of amide attachment to the chelator [~Nn]n in Formula I may similarly be attached at one of any possible positions on the phenyl ring. R3 and R4 are independently selected from the group consisting of: H, OH, NH2, COCH3, COPh, OPh, NHPh, CN, N02, C02H, C02CH3, I; Br and Cl.
Sensitizers of the present invention belonging to the quinoline class can be further categorized into 3- aminoquinolines (3AQ), and 6-aminoquinolines (6AQ).
Preferably in the quinoline compounds of the present invention, Rl is selected from the group consisting IO of:

\ \ NH2 H2N \ \

wherein R3 and R4 are as defined herein above.
The linker R2 is an amine or other moiety having a functional group that can bioconjugate or can be derivatized to couple with biomolecules. In a preferred embodiment of the present invention, R2 is selected from the group consisting of: OH, NH(CH2)nOH, NH(CH2)nNH2, NH(CH2)nPhNH2, NH(CH2)nPhOH, NHCH(C02H)CH2PhNH2,, NH(CH2)nPhNCS; wherein n is 1-12. The present invention also contemplates the use of other linkers known in the art for coupling.
Particularly preferred compounds of the present invention include the DTPA
chelates listed in Table II below:
Table II

Formula R1 R2 Lifetime msec Lanthanide Eu Tb I 3AAP - 0.59 1.73 I 3AQ - 0.59 I 6AQ - 0.60 I 4ABP - 0.60 1.03 I 3AAP 4APEA 0.50 1.62 I 3AAP 4APEA-ITC 0.62 1.65 I 3AAP 4APA 0.60 1.70 I 6AQ CAD 0.58 I 4ABP 4APEA 0.43 0.73 I 4ABP CAD 0.59 0.82 Abbreviations:
3AAP: 4-aminoacetophenone 3AQ: 3-aminoquinoline 6AQ: 6-aminoquinoline 4ABP: 4-aminobenzophenone 4APEA: 4-aminophenethylamine 4APEA-ITC: 4-isothiocyanatophenethylamine 4APA: 4-aminophenylalanine DTPA: Diethylene-triamine-pentaacetic acid TTHA: Triethylene-tetramine-hexaacetic acid CAD: Cadaverine or 1,5-diaminopentane More particularly preferred compounds of the present invention include the DTPA
chelates below:
% O / / O /
\ \ \ \
NH ~ v ~NH
O O
7-amino-1-azaxanth-5-one 2-amino-xanthone (7AAX) (2AX) N / NH / O j NH
\ ) \
v O O N
3-amino-acridone 2-amino-3-cyano-azaxanthone (3AAC) (2ACAX) / O j NH / O N NH
\I \
Br N \N
O O

2-amino-3-cyano-7-bromo-azaxanthone 2-amino-3-cyano-7-ethyl-azaxanthone (2ACBAX) {2ACEAX) Dei'initions Sensitizes and chelator moiety abbreviations are as defined in Table II above.
The terms "bioconjugate" and "bioconjugatable" mean the ability of a functional group or groups on a chemical moiety to form covalent linkage to biomolecules.
The term "polycarboxylate derivative of DTPA or TTHA" means a compound which differs from DTPA and TTHA by changing the length of N-acetic acid units, or by rearranging the units from a linear to a cyclic form.
The term "bioassay" means immunoassays, DNA hybridization assays, receptor binding assays, enzyme assays, cell-based assays, immunocytochemcial or immunohistochemical assays and the like.
Method of Preparation The sensitizers and space linkers with structures described herein above are employed in a manner shown in Scheme I and in the Examples. The first step in the synthetic route involves reacting the sensitizes amine, hereby exemplified by aminoacetophenone, with equal or higher molar ratio of DTPAA (diethylene-triamine-pentaacetic anhydride) in the presence of triethylamine. The product formed is not isolated but allowed to react with an equal or a slight molar excess of the linker amine, hereby exemplified by 4-aminophenethylamine. The disubstituted derivative is then isolated and purified by HPLC before convening the linker amino group into a bioconjugatable function. The final step is to react the product (Compound 5} with thiophosgene in a slightly acidic condition to form the isothiocyanate (Compound 6).
Alternatively, a chlorotirazine derivative instead of an isothiocyanate can also be prepared from Compound 5 for facile labelling of target molecules with a reactive amino function.

WO 00/O1b63 PCT/US99/15366 \ a HsC \ ~ b ~ H ~ O --HC
s ~ NHZ O N~\ /~N~
N O
O ~O
O OH
OH
NHZ
O O
HaC \ \ C
H~ ~H
O N~ ~N ~'"
N O
O OH ~ O OH
off s O O / ~ Ni H3C \ H~ ~H \
O N~ SIN
N O
O OH ~ O OH
OH
a) DTPAA, DMSO, Et3N; b) 4APEA, DMSO, Et3N; c) CSC12, MeCl2-H2O
Utility of the Invention The compounds of this invention can be used for labelling donor peptides, proteins, DNAs, enzyme substrates, ligand molecules in immunoassays, DNA hybridization assays, receptor binding assays, enzyme assays, cell-based assays, immunocytochemcial or immunohistochemical assays and the like. These bioassays can be also formated for ultrasensitive high-throughput screening assays. In the bioassay, the lanthanide chelate is excited in a fluorescence instrument and provide energy transfer to an acceptor molecule such as an organic dye (e.g. allophycocyanin (APC), or indodicarbocyanin or CY-5) capable of providing the desired long-lived fluorescense emission for quantitation.
The present invention also provides a method for using the compounds of Formula I in fluorescence detection-based techniques or bioassays. The present method comprises the steps of:
labelling an aliquot comprising donor biomolecules selected from the group consisting of: peptides, proteins, deoxyribonucleic acids (DNAs), ribonucleic acids (RNAs), enzyme substrates, and ligand molecules with a compound of Formula I
by a linking reaction with linker R2 to provide a labelled biomolecule assay sample;
2. adding a suitable amount of a suitable organic dye, preferably selected from the group consisting of: allophycocyanin (APC) and indodicarbocyanin (CY-5), to the labelled biomolecule assay sample;
3. exciting the labelled biomolecule assay sample in a suitable fluorescence instrument to provide a fluorescense emission for quantitation.
Fluorescence instruments suitable for use in the inventive method include the Photon Technology International, Model LS-100, Luminescence System.
The present invention further provides a kit for fluorescence detection-based techniques or bioassays which use the compounds of Formula I as the basis for signal detection and measurement, such kit comprising:
1. a suitable amount of a compound of Formula I; and 2. a suitable amount of organic dye, preferably selected from the group consisting of: allophycocyanin (APC), indodicarbocyanin (CY-5) and rhodamine.
Such a kit provides instructions for proper use thereof, including the appropriate amounts of the compound of Formula I and the organic dye to use for a particular bioassay sample molecular type and size.
General Proton NMR spectra were recorded at 400 MHz using a Bruker AMX 400 spectrometer. CDC13 is deuteriochloroform, DMSO-d6 is hexadeuteriodimethylsulfoxide, and) CD30D is tetradeuteriomethanol. Chemical shifts are reported in parts per million (d) downfield from the internal standard tetramethylsilane. Abbreviations for NMR
data are as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, app = apparent, br = broad. J indicates the NMR coupling constant measured in Hertz. Fourier transform infrared (FTIR) spectra were recorded on a Nicolet Impact 400 D infrared spectrometer. IR and FTIR spectra were recorded in transmission mode, and band positions are reported in inverse wavenumbers (cm'1). Mass spectra were taken on either VG 70 FE, PE Syx API III, or VG ZAB HF
instruments, using fast atom bombardment (FAB) or electrospray (ES) ionization techniques.

Examples In the following synthetic examples, temperature is in degrees Centigrade (°C).
Unless otherwise indicated, all of the starting materials were obtained from commercial sources. Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent.
These Examples are given to illustrate the invention, not to limit its scope. Reference is made to the claims for what is reserved to the inventors hereunder.
Referring to Table II and the Method of Preparation section:
Example 1 Preparation of 3AAP-DTPA (1) and 3AAP-DTPA-4APEA (5) To a solution of DTPAA ( 143 mg, 0.4 mmol) in 10 mL dry DMSO and 2 mL dry triethylamine was added a solution of 3-arninoacetophenone (3AAP, 54 mg, 0.4 mmol) in 5 mL DMSO. The mixture was stirred at room temperature for 0.5 h and then treated with a solution of 4-aminophenethylamine (4APEA, 53 mg, 0.4 mmol) in 5 mL DMSO. The mixture was allowed to stir at room temperature for an additional 3 h and then evaporated to dryness. The oily residue was chromatographed on reversed-phase C 18 hpic (using a step gradient of 0 to 60% acetonitrile in 0.1 % TFA buffer) to give, after Iyophilization, 1 as a cream colored solid and 5 as a pale yellow solid. Compound 1 was obtained in 59 mg yield. 1H-NMR (CD30D) : d 2.60 (3H, s), 3.1-3.5 (IOH, m), 3.6 (2H, s), 3.65 (2H, s), 3.71 (2H, s), 4.42 (2H, s), 7.42 ( 1 H, dd), 7.75 ( 1 H, dd), 7.83 ( 1 H, dd), 8.31 ( 1 H, d); MS: m/z 511 (M-H), Compound 5 was obtained in 16 mg yield. 1 H-NMR (CD30D): d 2.62 (3H, s), 2.73 (2H, t), 3.21 (2H, t), 3.3-3.55 ( 12H, m), 3.65 (2H, s), 3.74 (2H, s), 4.35 (2H, s), 7.13 (4H, s), 7.41 ( 1 H, dd), 7.75 ( 1 H, dd), 7.83 ( 1 H, dd), 8.32 ( 1 H,d); MS
: m/z 682 (M+ 3NH4), 683 (MH+ 3NH4).
Example 2 Preparation of 4AAP-DTPA-APEA-ITC (6).
To a solution of 4AAP-DTPA-APEA (3, 12 mg, 0.019 mmol) in 10 mL of 0.5 N
HCl was added 4mL of thiophosgene (85% in CC14). The two phase reaction was allowed to stirred vigorously for I h . The mixture was worked up by separating the layers in a separatory funnel and the aqueos solution was washed by additional methylene chloride and then chromatographed on a small reversed-phase C18 column to give the thioisocyanate WO 00/OI663 PCT/US99/t5366 product (6), an off white solid in 10 mg yield after lyophilization. 1H-NMR
(CD30D):
2.60 (3H, s), 2.72 (2H, t), 3.20 {2H, t), 3.3-3.5 ( 12H, m), 3.65 (2H, s), 3.74 (2H, s), 4.34 (2H, s), 7.12 (4H, s), 7.41 ( 1 H, ss), 7.74 ( I H, dd), 7.84 ( 1 H, dd), 8.20 ( I H,d); MS: m/z 724 (M+3NH4), 725 (MH+ 3NH4); IR: 2108 cm-1 (S=C=N stretch).
Example 3 Preparation of 4ABP-DTPA (4) and 4ABP-DTPA-4APEA (12) To a solution of DTPAA (179 mg, 0.5 mmol) in 5 mL of dry DMSO and 3 mL of dry triethylamine was added a solution of 4-aminobenzophenone (4ABP, 99 mg, 0.5 mmol) in 5 mL DMSO. The mixture was stirred for 0.5 h and treated with a solution of aminophenethylamine (4APEA, 68 mg, 0.05 mmol) in 5 mL DMSO. After an additional 3 h stirnng at room temperature, the mixture was evaporated to dryness. The oily residue was chromatographed on reversed-phase C 18 hplc (using a step gradietn of 0-60%
acetonitrile in 0.1 % TFA buffer) to give 4 as a cream colored solid and 12 as a pale yellow solid. Compound 4 was obtained in 57 mg yield. 1H-NMR {CD30D): d 3.2-3.5 (IOH, m), 3.60 (2H, s), 3.63 (2H, s), 3.74 (2H, s), 4.43 (2H, s), 7.53 (2H, m), 7.62 ( 1 H, dd), 7.76 (2H, m), 7.8 (4H, s); MS: mlz 573 (M+H). Compound 12 was obtained in 47 mg yield.
IH-NMR (CD30D): d 2.73 (2H, t), 3.25 (2H, t), 3.3-3.5 (12H, m), 3.67 (2H, s), 3.73 (2H, s), 4.3 (2H, s), 7.23 (4H, s), 7.55 (2H, m), 7.64 (1H, dd), 7.8 (2H, m), 7.83 (4H, m); MS:
mlz 691 (M+H).
The above specification and Examples fully disclose how to make and use the compounds of the present invention. However, the present invention is not limited to the particular embodiments described hereinabove, but includes all modifications thereof within the scope of the following claims. The various references to journals, patents and other publications which are cited herein comprise the state of the art and are incorporated herein by reference as though fully set forth.

Claims (10)

We claim:
1. A compound of Formula I:
[\N~]n is a chelator selected from the group consisting of: DTPA (n= 1), (TTHA) (n=2), and a polycarboxylate derivative of DTPA or TTHA, which chelates a lanthanide metal cation;
R1 is selected from the group consisting of: phenones and quinolines; and R2 is selected from the group consisting of: OH, NH(CH2)n OH, NH(CH2)n NH2, NH(CH2)n PhNH2, NH(CH2)n PhOH, NHCH(CO2H)CH2PhNH2, NH(CH2)n PhNCS;
wherein n is 1-6.
2. A compound according to Claim 1 wherein R1 is selected from the following group: aminoacetophenones (AAP), aminobenzophenones (ABP), aminofluorenones (AF), aminoxantones (AX), amino-azaxanthones (AAX), aminoanthraquinones (AAQ), aminoacridones (AAC), and aminoquinolines (AQ):

wherein R3 and R4 are independently selected from the group consisting of: H, OH, NH2, COCH3, COPh, OPh, NHPh, CN, NO2, CO2H, and CO2CH3.
3. A compound according to Claim 1 wherein R1 is selected from the following group:
4. A compound according to Claim 1 wherein [~N~]n is DTPA (n= 1).
5. A compound according to Claim 1 wherein the lanthanide metal cation is selected from the group consisting of: Tb III, Eu III, Sm III, and Dy III.
6. A compound according to Claim 5 wherein the lanthanide metal cation is selected from the group consisting of: Eu III or Tb III.
7. A method for using a compound of Formula I:
wherein:
[~N~]n is a chelator selected from the group consisting of: DTPA (n= 1), (TTHA) (n=2), and a polycarboxylate derivative of DTPA or TTHA, which chelates a lanthanide metal cation;
R1 is selected from the group consisting of: phenones and quinolines; and R2 is selected from the group consisting of: OH, NH(CH2)n OH, NH(CH2)n NH2, NH(CH2)n PhNH2, NH(CH2)n PhOH, NHCH(CO2H)CH2PhNH2, NH(CH2)n PhNCS;
wherein n is 1-6;
in fluorescence detection-based techniques or bioassays comprising the steps of:

a. labelling an aliquot comprising donor biomolecules selected from the group consisting of: peptides, proteins, deoxyribonucleic acids (DNAs), ribonucleic acids (RNAs), enzyme substrates, and ligand molecules with a compound of Formula I
by a linking reaction with linker R2 to provide a labelled biomolecule assay sample;
b. adding a suitable amount of a suitable organic dye to the labelled biomolecule assay sample;
c. exciting the labelled biomolecule assay sample in a suitable fluorescence instrument to provide a fluorescense emission for quantitation.
8. A method according to Claim 7 wherein said organic dye is selected from the group consisting of but not limited to: rhodamine, allophycocyanin (APC) and indodicarbocyanin (CY-5),
9. A kit for fluorescence detection-based techniques or bioassays comprising:
a. a suitable amount of a compound of Formula I; and b. a suitable amount of organic dye.
10. A kit according to Claim 9 wherein said organic dye is selected from the group consisting of but not limited to: rhodamine, allophycocyanin (APC) and indodicarbocyanin (CY-5).
CA002336904A 1998-07-07 1999-07-07 Novel fluorescent lanthanide chelates Abandoned CA2336904A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9194498P 1998-07-07 1998-07-07
US60/091,944 1998-07-07
PCT/US1999/015366 WO2000001663A1 (en) 1998-07-07 1999-07-07 Novel fluorescent lanthanide chelates

Publications (1)

Publication Number Publication Date
CA2336904A1 true CA2336904A1 (en) 2000-01-13

Family

ID=22230424

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002336904A Abandoned CA2336904A1 (en) 1998-07-07 1999-07-07 Novel fluorescent lanthanide chelates

Country Status (4)

Country Link
EP (1) EP1095011A4 (en)
JP (1) JP2002519404A (en)
CA (1) CA2336904A1 (en)
WO (1) WO2000001663A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440389B1 (en) * 2000-07-19 2002-08-27 The General Hospital Corporation Fluorescent agents for real-time measurement of organ function
CA2424370A1 (en) 2000-10-19 2002-04-25 Exxonmobil Chemical Patents Inc. Cationic group-3 catalyst system
DE10163295B4 (en) 2001-12-21 2004-03-25 Honeywell Specialty Chemicals Seelze Gmbh Rare earth metal compounds and mixtures thereof, processes for their preparation and their use
DE102004022628A1 (en) * 2004-05-07 2005-12-15 Sensient Imaging Technologies Gmbh FRET bioassay
DE102004024011A1 (en) * 2004-05-14 2005-12-01 Bayer Chemicals Ag Difluoro-1,3-dioxole
WO2006014645A1 (en) * 2004-07-23 2006-02-09 Amgen Inc. Generic probes for the detection of phosphorylated sequences
CN101010107A (en) * 2004-08-26 2007-08-01 马林克罗特公司 Luminescent metal complexes for monitoring renal function
EP1885817B1 (en) * 2005-05-11 2016-05-11 University Of Durham Responsive luminescent lanthanide complexes
DK1885817T3 (en) 2005-05-11 2016-08-22 Univ Durham Luminescent lanthanide OF RESPONSE
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
GB2451106A (en) * 2007-07-18 2009-01-21 Cis Bio Int Lanthanide (III) ion complexing pyrazoyl-aza(thio)xanthone comprising compounds, their complexes and their use as fluorescent labels
EP2480891B1 (en) 2009-09-24 2016-11-23 INSERM - Institut National de la Santé et de la Recherche Médicale Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
HUE045270T2 (en) 2010-01-05 2019-12-30 Inst Nat Sante Rech Med Flt3 receptor antagonists for the treatment or the prevention of pain disorders
DE102011001368B4 (en) 2011-03-17 2013-01-31 Bundesanstalt für Materialforschung und -Prüfung (BAM) Lanthanoid chelates containing particles, their preparation and their use in bioanalysis
DE102011101207B3 (en) 2011-05-11 2012-05-10 Sartorius Stedim Biotech Gmbh Fluorescent dye for pH sensor
EP2710381A2 (en) 2011-05-16 2014-03-26 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for screening substances capable of modulating the replication of an influenza virus
US20150276760A1 (en) 2012-10-04 2015-10-01 INSERM (Institut National de la Sante Et de la Recherche Medicate) Method for Screening a Compound Capable of Inhibiting the Notch1 Transcriptional Activity
DK3108255T3 (en) 2014-02-18 2020-11-09 Inst Nat Sante Rech Med PROCEDURES AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES MEDIATED BY NRP-1 / OBR COMPLEX SIGNAL ROUTE
EP3131922B1 (en) 2014-04-17 2020-05-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides and uses thereof for reducing cd95-mediated cell motility
WO2020144324A1 (en) 2019-01-11 2020-07-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for screening inhibitors against chikungunya virus and for determining whether subjects are predisposed to infection by said virus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162508A (en) * 1987-12-18 1992-11-10 Compagnie Oris Industrie Rare earth cryptates, processes for their preparation, synthesis intermediates and application as fluorescent tracers
US5622821A (en) * 1994-06-29 1997-04-22 The Regents Of The University Of California Luminescent lanthanide chelates and methods of use
DE19505960A1 (en) * 1995-02-21 1996-08-22 Deutsches Krebsforsch Conjugate for the individual dosage of drugs
GB9813776D0 (en) * 1998-06-25 1998-08-26 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
EP1095011A1 (en) 2001-05-02
JP2002519404A (en) 2002-07-02
WO2000001663A1 (en) 2000-01-13
EP1095011A4 (en) 2003-01-08

Similar Documents

Publication Publication Date Title
CA2336904A1 (en) Novel fluorescent lanthanide chelates
JP5335236B2 (en) Lanthanide chelates and their use in bioassays
US5132432A (en) Chemically reactive pyrenyloxy sulfonic acid dyes
JP5548363B2 (en) Novel fluorescent dyes and their use
US8541555B2 (en) Hydrazone-based and oxime-based fluorescent and chromophoric/pro-fluorescent and pro-chromophoric reagents and linkers
CN106232771B (en) The new chromophore architectures of lanthanide chelate
US6277984B1 (en) Monomethine cyanines rigidized by a two-carbon chain
US6740756B1 (en) Fluorescent lanthanide chelates
US20210395606A1 (en) Chromophoric structures for macrocyclic lanthanide chelates
US6552199B1 (en) Fluorescence dyes and their use as fluorescence markers
US7297690B2 (en) Fluorescent lanthadine complex
US5958673A (en) Fluorescent dye
DE60214709T2 (en) Method for increasing the hydrophilicity of fluorescent marker compounds
US6441167B1 (en) Cinoxacin lanthanide chelates and their use as biomolecular probes
WO2008140452A1 (en) Novel hydrazone-based and oxime-based fluorescent and chromophoric/pro-fluorescent and pro-chromophoric reagents and linkers
JP2006234772A (en) Method of detecting protein and fluorescent dye used for same
EP4103652A1 (en) Fluorescent rhodamine dyes with enhanced cell permeability
US20040029290A1 (en) Fluorescent dye complexes
US5151517A (en) Derivatives of tetrahydro-2,3,6,7,1h,5h,11h-(1)benzopyrano(6,7,8,i,j)quinolizinone-11 usable as markers for organic compounds, particularly biological compounds with a view to their detection by chemiluminescence or fluorescence
CN115703771A (en) Fluorescent dye and preparation method and application thereof
Mihaela et al. Synthesis and biological application of a new 1, 2, 5-oxadiazolo [3, 4-c] pyridine moiety fluorescent marker

Legal Events

Date Code Title Description
FZDE Discontinued